Using an explant culture system, we have demonstrated that human somatotropes respond to growth hormone releasing factor (GRF) and somatostatin (SRIF) from as early as 9.5 weeks of fetal age. Responsiveness to GRF increases significantly as a function of age up to midgestation while SRIF inhibition of basal growth hormone (GH) release does not change. SRIF has little effect on GRF-stimulated GH secretion from early gestation pituitaries, but its ability to block GRF stimulation gradually increases with fetal age from 9.5 to 16 weeks. The response to GRF remains predominant throughout this developmental period : 100 times more SRIF than GRF must be added to the cultures in order to block the GRF stimulatory effect and maintain GH secretion at basal (control) levels. Finally, adding SRIF 30 min prior to the GRF does not increase the inhibitory activity of SRIF.
determine why serum GH levels are so high and fluctuate so dramatically during fetal life. Our previous studies have shown that fetal somatotropes can be stimulated in vitro by growth hormone releasing factor (GRF) and inhibited by somatostatin (SRIF) in a dose-related fashion (Goodyer et al., 1984) . Surprisingly, when GRF and SRIF were added together at the same concentrations, GRF blocked SRIF inhibition of GH release (Goodyer et al., 1984) , suggesting that stimulatory pathways predominate in the early gestation human fetal somatotrope. The present studies were undertaken to examine this hypothesis further.
Materials and methods.
Cultures. &horbar; Human fetal anterior pituitary glands (9.5-16 Streeter (1920 Results.
GRF + l -SRlF as a function of fetal age. - Figure 1 shows the effects of GRF, alone and in combination with SRIF, as a function of fetal age. In the upper panel GRF and SRIF were tested at the same concentration (10-8 M), while in the lower panel SRIF(10-8 M) was 10 fold higher than GRF(10-9 M). We found that, along with the previously recognized age-related increase in responsiveness to GRF110-$ or 10-9 M), there was an increase in the ability of SRIF(at 10-8 M) to inhibit GRF stimulation of GH release. This was especially apparent when SRIF was ten-fold higher in concentration than the GRF(lower panel). However (Gluckman, 1983) . Since these high GH concentrations do not appear to play a critical role in fetal growth or development, and because they gradually decrease during late gestation and the immediate postnatal period, it has been proposed that they are a consequence of immature control mechanisms (Kaplan and Grumbach, 1976 ; Gluckman, 1983 (Goodyer et al., 1984) . Responsiveness to GRF increases at each dose tested (10-$ -10-'° M) from the ninth week to midgestation (Goodyer et al. present data). In contrast, there is very little change in the inhibitory effect of SRIF(10-7 -10-1° M) on basal GH secretion during this same period of development (Goodyer et al., 
unpublished).
In a preliminary study (Goodyer et al., 1984) (Law et al., 1985 ; Sheppard et al., 1985 ; Cuttler et al., 1986) . That is, when GRF and SRIF interact at the level of the adult rat somatotrope, SRIF appears to exert the dominant influence on GH release.
Since our initial experiments were done with fairly early gestation human pituitary glands (n = 7, 9.5-11.5 weeks ; n = 1, 13.5 weeks), it was decided to repeat the study using glands from older fetuses. Another indication of the refractoriness of the fetal somatotrope to SRIF is that, in order to observe a marked inhibition of the GRF stimulatory effect, we had to add 10-100 times more SRIF than GRF. This was especially evident in the early gestation pituitary cultures. In addition, adding the somatostatin thirty minutes prior to the GRF did not appear to increase the efficacy of SRIF. These data support our previous hypothesis that the early to mid-gestation human fetal somatotrope is preferentially responsive to GRF and relatively insensitive to SRIF (Goodyer et al., 19841. ln vivo and in vitro studies of the rat somatotrope suggest that, in this species as well, GRF rather than SRIF is the major factor regulating GH secretion in the late gestation fetus (Rieutort, 1981 ; Khorram et al., 1983 ; Baird et al., 1984) . Following birth, there is a gradual decrease in responsiveness to GRF ; at the same time, SRIF slowly increases its influence on both basal and GRFstimulated GH secretion until in the adult it appears to play a critical role in regulating GH release (Walker et al., 1977 ; Rieutort, 1981 ; Bowers et al., 1981 ; Oliver et al., 1982 ; Khorram et al., 1983 ; Celia et al., 1985 ; Szabo and Cuttler, 1986 ; Cuttler et al., 1986 ; Wehrenberg, 1986) .
A comparison of the human and rat studies suggests that development of the hypothalamic-somatotrope axis may be occuring in a similar fashion in the two species although the timing in relation to parturition differs considerably. Unfortunately, we can only speculate as to what mechanisms are involved during these ontogenetic changes, since so few data are as yet available. Because human and rat fetal somatotropes respond to both GRF and SRIF, specific receptors for both peptides must be present on these cells. However, the difference in relative responsiveness suggests that, during early stages of development, either the GRF receptor exists in greater number or the GRFreceptor complex interacts more efficiently with its transducing systems than the SRIF-receptor complex. Studies of the ACTH receptor in ovine fetal adrenals (Durand et al., 1985) and of the /3-adrenergic receptor in rabbit fetal lung (Roberts et al., 1984) Nos données suggèrent que les mécanismes qui permettent l'interaction entre la somatostatine et le GRF dans la cellule somatotrope foetale évoluent relativement lentement entre la 9 e et la 16&dquo; semaine de gestation mais privilégient l'action stimulante du GRF. Ces résultats peuvent expliquer les niveaux élevés d'hormone de croissance observés chez le foetus pendant la première moitié de la vie foetale.
